CONFIDENTIALITY AND INVENTIONS ASSIGNMENT AGREEMENT November 16, 2018Confidentiality and Inventions Assignment Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
In consideration and as a condition of my employment, or continued employment, by Advance Biofactures Corp., a New York corporation (the “Company”), and the compensation now and hereafter paid to me, I hereby agree as follows:
FIFTH AMENDMENT TO RIGHTS AGREEMENTRights Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This FIFTH AMENDMENT (this “Amendment”), dated as of May 11, 2018, to the RIGHTS AGREEMENT, dated as of May 14, 2002, as amended on June 19, 2003, and as further amended on of February 3, 2011, March 5, 2014 and May 27, 2016 (the “Rights Agreement”), between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), and Worldwide Stock Transfer, LLC (as successor in interest to OTC Corporate Transfer Service Company) as Rights Agent (the “Rights Agent”).
FOURTH AMENDMENT TO RIGHTS AGREEMENTRights Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
This FOURTH AMENDMENT (this “Amendment”), dated as of May 27, 2016, to the RIGHTS AGREEMENT, dated as of May 14, 2002, as amended on June 19, 2003, and as further amended on of February 3, 2011 and March 5, 2014 (the “Rights Agreement”), between BioSpecifics Technologies Corp., a Delaware corporation (the “Company”), and Worldwide Stock Transfer, LLC (as successor in interest to OTC Corporate Transfer Service Company) as Rights Agent (the “Rights Agent”).
Patrick M. Caldwell Amended and Restated Indemnification AgreementIndemnification Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations
In connection with the engagement of Patrick M. Caldwell ("PMC") to advise and assist the undersigned (together with its affiliates and subsidiaries, referred to as the "Company") with the matters set forth in the oral agreement between the Company and PMC (the "Agreement"), in the event that PMC becomes involved in any capacity in any claim, suit, action, proceeding, investigation or inquiry (including, without limitation, any stockholder or derivative action or arbitration proceeding) (collectively, a "Proceeding") in connection with any matter in any way relating to or referred to in the Agreement or arising out of the matters contemplated by the Agreement, including, without limitation, related services and activities prior to the date of the Agreement, the Company agrees to indemnify, defend and hold PMC harmless to the fullest extent permitted by law, from and against any losses, claims, damages, liabilities and expenses in connection with any matter in any way relating to or ref
CONSULTING AGREEMENT Effective Date: April 1, 2019Consulting Agreement • April 2nd, 2019 • Biospecifics Technologies Corp • Pharmaceutical preparations • New York
THIS CONSULTING AGREEMENT (this “Agreement”), is entered into by and between BioSpecifics Technologies Corporation, a Delaware corporation (“BSTC” or the “Company”), and Pat Caldwell, an individual, with a primary address at 13485 Harding Avenue, San Martin, California 95046 (“Consultant”), as of the date set forth above (the “Effective Date”). BSTC and Consultant may each be referred to as a “Party” or together, the “Parties”.
